HK Stock Market Move | CH BEIDAHUANG (00039) is now up more than 10%, with its mid-term losses narrowing by 36.5% year-on-year.
China Beidahuang (00039) resumed trading after nearly 3 months and soared nearly 89% this morning, but the increase has noticeably narrowed.
CH BEIDAHUANG (00039) resumed trading after nearly 3 months, with the stock surging nearly 89% this morning, but the gain has since narrowed. As of the time of writing, it is up 10.23% at 0.097 Hong Kong dollars, with a trading volume of 6.6724 million Hong Kong dollars.
In terms of news, CH BEIDAHUANG released its financial results for the six months ended June 30, 2025, with revenue of 158 million Hong Kong dollars, a 62% year-on-year increase; the company's attributable loss to owners narrowed by 36.5% to 38.389 million Hong Kong dollars, with a basic loss per share of 0.50 Hong Kong cents. The announcement stated that the group will continue to control costs and focus existing resources to strengthen and develop the group's business through internal expansion and acquisitions at the right time.
The group believes that its business portfolio has become diversified over the past few years. It will focus on existing businesses and expand through internal development and investments in similar businesses. The company will carefully select investments from all options and collaborate with experienced business partners for operations.
Related Articles

HAOHAI BIOTEC (06826) spent HKD 2.1994 million to repurchase 78,900 shares on November 27th.

PRU (02378) spent 3.06 million pounds to repurchase 284,000 shares on November 26th.
.png)
Autobio Diagnostics (603658.SH) and its subsidiaries have obtained multiple medical device registration certificates.
HAOHAI BIOTEC (06826) spent HKD 2.1994 million to repurchase 78,900 shares on November 27th.

PRU (02378) spent 3.06 million pounds to repurchase 284,000 shares on November 26th.

Autobio Diagnostics (603658.SH) and its subsidiaries have obtained multiple medical device registration certificates.
.png)
RECOMMEND

Hong Kong Stock Buyback Wave Persists, 247 Listed Companies Repurchase Over HKD 150 Billion This Year
27/11/2025

Mingyu Pharmaceutical Files With HKEX: Ongoing Net Losses Since Inception, No Revenue From Commercial Product Sales
27/11/2025

“Affordability Crisis”! Consumer Confidence Falls To Second Lowest Since The Pandemic, U.S. Retail Slumps
27/11/2025


